# Invasive Fungal Infections During Extracorporeal Membrane Oxygenation: A Case Series from Intensive Care Unit and Literature Review

**Authors:** Francesca Serapide, Riccardo Serraino, Angelo Feola, Helen Linda Morrone, Vincenzo Olivadese, Giuseppe Neri, Eugenio Biamonte, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Alessandro Russo

PMC · DOI: 10.3390/diagnostics16040505 · Diagnostics · 2026-02-07

## TL;DR

This study reports on the high mortality rate of invasive fungal infections in patients on ECMO in an ICU, emphasizing the need for better diagnostics and treatment strategies.

## Contribution

The study provides a case series and literature review on invasive fungal infections during ECMO, highlighting mortality and co-infections.

## Key findings

- 15.7% of ECMO patients developed invasive fungal infections, with a 91% mortality rate.
- Invasive candidiasis was the most common infection, and many patients had co-infections with MDR bacteria.

## Abstract

Background: Extracorporeal membrane oxygenation (ECMO) support is associated with potentially life-threatening complications, among which nosocomial infections play a significant role. The increasing incidence of fungi as causative agents of ECMO-associated infections is a growing concern. Methods: This case series includes all patients admitted to the Intensive Care Unit (ICU) of the “Renato Dulbecco” Teaching Hospital in Catanzaro who developed invasive fungal infections (IFIs) during ECMO support. Results: Of the 70 patients, 15.7% (N = 11) developed IFIs during ECMO. Among these, 91% (N = 10) died, while one patient survived and was discharged. Of the IFIs, 72.7% (N = 8) were cases of invasive candidiasis (IC), and 18.2% (N = 2) were cases of invasive pulmonary aspergillosis (IPA). One patient developed both IC and IPA during ECMO treatment. Additionally, 54.5% (N = 6) of the patients with IFIs also had bacterial co-infections, most of which were caused by multidrug-resistant (MDR) Gram-negative bacteria. Conclusions: This study highlights the high incidence and mortality of IFIs in ECMO patients. It underscores the urgent need for clear definitions, better diagnostic strategies, pharmacokinetic data on antifungal therapies, and the implementation of therapeutic drug monitoring (TDM) to optimize outcomes in this vulnerable population.

## Linked entities

- **Diseases:** invasive candidiasis (MONDO:0044067)

## Full-text entities

- **Diseases:** Infections (MESH:D007239), ischemic heart disease (MESH:D017202), COVID-19 (MESH:D000086382), bacterial co-infections (MESH:D060085), nosocomial infection (MESH:D003428), IC (MESH:D058365), Mortality (MESH:D003643), C. parapsilosis (OMIM:211750), CRRT (MESH:D014202), Fungal Infections (MESH:D009181), Aspergillus infection (MESH:D001228), IFIs (MESH:D000072742), tract colonization (MESH:D003108), invasive (MESH:D009361), Infectious Diseases (MESH:D003141), sepsis (MESH:D018805), bacterial (MESH:D001424), TDM (MESH:D000081015), renal impairment (MESH:D007674), IPA (MESH:D055744), Candida infections (MESH:D002177), NHL (MESH:D008228), renal failure (MESH:D051437), candidemia (MESH:D058387), aortic dissection (MESH:D000784), neutropenic (MESH:D044504), anuria (MESH:D001002), respiratory tract (MESH:D012141), injury to (MESH:D014947), HL (MESH:C538324), critically ill (MESH:D016638), pulmonary aspergillosis (MESH:D055732), H1N1 influenza (MESH:D007251), ICs (MESH:C535741), ARDS (MESH:D012128), pleural effusion (MESH:D010996), acute respiratory failure (MESH:D012131), obesity (MESH:D009765), Hodgkin lymphoma (MESH:D006689), H1N1 influenza pneumonia (MESH:D011014)
- **Chemicals:** Isavuconazole (MESH:C508735), amphotericin B (MESH:D000666), oseltamivir (MESH:D053139), BDG (-), L-AmB (MESH:C068538), caspofungin (MESH:D000077336), Fluconazole (MESH:D015725), triazole (MESH:D014230), GM (MESH:C012990), cefiderocol (MESH:C000612166), azole (MESH:D001393), tigecycline (MESH:D000078304), deoxycholate (MESH:D003840), echinocandins (MESH:D054714), voriconazole (MESH:D065819), methicillin (MESH:D008712), V (MESH:D014639), Posaconazole (MESH:C101425), vancomycin (MESH:D014640), carbapenem (MESH:D015780)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Candida [taxon 1535326], Lodderomyces parapsilosis (species) [taxon 5480], Enterococcus faecium (species) [taxon 1352], Acinetobacter baumannii (species) [taxon 470], Nakaseomyces glabratus (species) [taxon 5478], Aspergillus fumigatus (species) [taxon 746128], Candida albicans (species) [taxon 5476], Fungi (kingdom) [taxon 4751]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939196/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939196/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939196/full.md

---
Source: https://tomesphere.com/paper/PMC12939196